newsfilter
← Latest News
PR Newswire·

Eiger BioPharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

Peginterferon lambda COVID-19 EUA Application to be Submitted in Q2 2022 Phase 3 HDV D-LIVR (lonafarnib) Study Topline Data Anticipated by Year End Zokinvy® (lonafarnib) CHMP Opinion Expected in Q2 2022 Phase 3 Avexitide Congenital Hyperinsulinism P